Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2012, Article ID 740279, 11 pages
http://dx.doi.org/10.1155/2012/740279
Clinical Study

Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

1Department of Hematology, Oncology and Palliative Care, Sarcoma Center Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, 15526 Bad Saarow, Germany
2Department of Medical Oncology, Christie Hospital, Wilmslow Road, Withington, Manchester M 204 BX, UK
3Medical Oncology Unit, Institut Català d'Oncologia, Gran Via, s/n km 2,7, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
4Sezione di Chemioterapia dei Tumori dell’Apparato Locomotore, Istituto Ortopedico Rizzoli, Via Pupilli 1, 40136 Bologna, Italy
5Hospital Son Dureta, Andrea Doria 55, 07014 Palma de Mallorca, Spain
6Department of Clinical Oncology, Leiden University Medical Center (LUMC), Albinusdreef 2, 2333 ZA Leiden, The Netherlands
7Health Economic Statistics, Merck Research Laboratories, Upper Gwynedd, PA 19454, USA
8Global Health Outcomes, Merck Research Laboratories, Whitehouse Station, NJ 08889, USA
9Ingenix Pharmaceutical Services AB, Optum Insight, Klarabergsviadukten 90, Hus D, 11164 Stockholm, Sweden
10Pennsylvania Hematology Oncology Associates, 230 West Washington Square, 2nd Floor, Philadelphia, PA 19106, USA
11Department of Medical Oncology, University Claude Bernard Lyon I, 43 Boulevard du 11 Novembre 1918, 69622 Villeurbanne cedex, Lyon, France

Received 15 November 2011; Accepted 23 December 2011

Academic Editor: Charles Scoggins

Copyright © 2012 Peter Reichardt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “SEER stat fact sheets: soft tissue including heart,” 2011, http://seer.cancer.gov/statfacts/html/soft.html.
  2. F. Ducimetière, A. Lurkin, D. Ranchère-Vince et al., “Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing,” PLoS ONE, vol. 6, no. 8, Article ID e20294, 2011. View at Publisher · View at Google Scholar
  3. J.-M. Coindre, P. Terrier, L. Guillou et al., “Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers sarcoma group,” Cancer, vol. 91, no. 10, pp. 1914–1926, 2001. View at Publisher · View at Google Scholar
  4. P. G. Casali and J. Y. Blay, “Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, supplement 5, pp. v198–v203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Athanasou, S. Bielack, E. de Alava et al., “Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, supplement 5, pp. v204–v213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. S. Bielack and D. Carrle, “State-of-the-art approach in selective curable tumors: bone sarcoma,” Annals of Oncology, vol. 19, supplement 7, pp. vii155–vii160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Wibmer, A. Leithner, N. Zielonke, M. Sperl, and R. Windhager, “Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review,” Annals of Oncology, vol. 21, no. 5, pp. 1106–1111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Drummond, B. J. O'Brien, G. L. Stoddart, and G. Torrance, Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press, Oxford, UK, 2nd edition, 1997.
  9. P. Dolan, “Modeling valuations for EuroQol health states,” Medical Care, vol. 35, no. 11, pp. 1095–1108, 1997. View at Google Scholar · View at Scopus
  10. P. Kind, “The EuroQol instrument: an index of health-related quality of life,” in Quality of Life and Pharmacoeconomics in Clinical Trials, B. Spilker, Ed., pp. 191–201, Lippincott-Raven, Philadelphia, Pa, USA, 1996. View at Google Scholar
  11. A. Poveda, A. López-Pousa, J. Martín et al., “Phase II clinical trial with pegylated liposomal doxorubicin (CAELYX/Doxil) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas: a study of the Spanish Group for Research in Sarcomas (GEIS),” Sarcoma, vol. 9, no. 3-4, pp. 127–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. P. Chawla, J. Blay, I. L. Ray-Coquard et al., “Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT),” Journal of Clinical Oncology, vol. 29, (supplement; abstract: 10005), 2011. View at Google Scholar
  13. J. W. Shaw, J. A. Johnson, and S. J. Coons, “US valuation of the EQ-5D health states: development and testing of the D1 valuation model,” Medical Care, vol. 43, no. 3, pp. 203–220, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater, “Interpreting the significance of changes in health-related quality-of-life scores,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 139–144, 1998. View at Google Scholar · View at Scopus
  15. S. J. Walters and J. E. Brazier, “Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D,” Quality of Life Research, vol. 14, no. 6, pp. 1523–1532, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. K. E. Muller and B. A. Fetterman, Regression and ANOVA: An Intergrated Approach Using SAS Software, SAS Institute, Cary, NC, USA, 2002.
  17. H. Michelson, C. Bolund, B. Nilsson, and Y. Brandberg, “Health-related quality of life measured by the EORTC QLQ-C30—reference values from a large sample of the Swedish population,” Acta Oncologica, vol. 39, no. 4, pp. 477–484, 2000. View at Google Scholar · View at Scopus
  18. E. J.O. Soini, B. G. San Andrés, and T. Joensuu, “Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information,” Annals of Oncology, vol. 22, no. 1, pp. 215–223, 2011. View at Publisher · View at Google Scholar
  19. N. Kontodimopoulos, V. H. Aletras, D. Paliouras, and D. Niakas, “Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments,” Value in Health, vol. 12, no. 8, pp. 1151–1157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. E. L. Simpson, R. Rafia, M. D. Stevenson, and D. Papaioannou, “Trabectedin for the treatment of advanced metastatic soft tissue sarcoma,” Health Technology Assessment, vol. 14, supplement 1, pp. 63–67, 2010. View at Google Scholar · View at Scopus